Bryan Blair, MD
Ophthalmology · Crestwood, KYNPI 1417945478
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,672 of the $6,623 with a category attached, or 85.6%. 26 manufacturers reported payments, led by Alcon at 41.2% of the total.
Across 241 payments — averaging $27.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- AbbVie$849
- Johnson & Johnson Surgical Vision, Inc.$382
- Ocular Therapeutix, Inc.$357
- Novartis$325
- Sun Pharmaceutical Industries Inc.$276
- plus $2K from 20 others
What the payments were for
- Travel & lodging$80812%
- Food & beverage$5,67286%
- Education$981%
- Gifts$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 74 | $2,727 |
| AbbVie(2 entities) | 32 | $849 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $382 |
| Ocular Therapeutix, Inc. | 25 | $357 |
| Novartis | 20 | $325 |
| Sun Pharmaceutical Industries Inc. | 13 | $276 |
| Oyster Point Pharma, Inc. | 11 | $224 |
| Harrow Eye, LLC | 6 | $205 |
| Tarsus Pharmaceuticals, Inc. | 4 | $202 |
| NEW World Medical,inc. | 4 | $168 |
| Mallinckrodt Hospital Products Inc. | 5 | $160 |
| Amgen(2 entities) | 10 | $147 |
| ANI Pharmaceuticals, Inc. | 4 | $119 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Rxsight Inc | 1 | $59 |
| Aerie Pharmaceuticals, Inc. | 3 | $55 |
| Dompe US, Inc. | 2 | $49 |
| Omeros Corporation | 4 | $49 |
| Ivantis, Inc | 3 | $45 |
| Rayner Intraocular Lenses Limited | 2 | $36 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $35 |
| Glaukos Corporation | 1 | $24 |
| Boston Scientific | 1 | $20 |
| Kala Pharmaceuticals, Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$245
- ReSTOR$125
- Clareon PanOptix Pro$125
- VEVYE$124
- XDEMVY$120
- VUITY$118
- Hydrus Microstent$115
- DEXTENZA$111
- AcrySof IQ PanOptix UV IOL$108
- AcrySof IQ VIVITY$108
- Tecnis IOL$105
- DURYSTA$101
How this compares
$6,623 in reported general payments places this provider in the 85th percentile of 216 ophthalmology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $62,664 |
| LumiganBimatoprost | 164 | $60,156 |
| XiidraLifitegrast | 26 | $25,107 |
| XdemvyLotilaner | 13 | $24,567 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $22,678 |
| TyrvayaVarenicline Tartrate | 17 | $13,380 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $12,470 |
| VevyeCyclosporine | 15 | $10,826 |
| VyzultaLatanoprostene Bunod | 28 | $10,302 |
| Brimonidine Tartrate | 173 | $10,145 |
| Alphagan PBrimonidine Tartrate | 38 | $9,503 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $9,154 |
| RhopressaNetarsudil Mesylate | 24 | $8,173 |
| Travoprost | 37 | $6,892 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,980 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $849 | $144,792289 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $61 | $35,40954 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $55 | $30,85163 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $202 | $24,56713 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $224 | $13,38017 claims |
| Harrow Eye, LLCVevye | $205 | $10,82615 claims |
| AlconSimbrinza | $2,727 | $5,98021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 216 ophthalmology providers in Kentucky.
Other ophthalmology in Crestwood
- Edward HollandEdgewood$678K
- Gary WortzLexington$159K
- Jeremy ClarkLouisville$131K
- Bruce KofflerLexington$49K
- Guruprasad PattarLouisville$36K
- Jeffery TaylorPaducah$18K
- Asim PirachaLexington$17K
- Gary FoulksLouisville$16K
- Christopher ComptonLouisville$13K
- Ryan SmithLexington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.